Hepatitis C treatment has been transformed by direct-acting antivirals (DAAs) achieving cure rates above 95% in 8-12 weeks. The field has shifted from drug development to elimination strategies, addressing populations that haven’t been reached, and managing complications in cured patients. For patients with hepatitis C, clinical trials for hepatitis c are now less common but still active in specific scenarios. This guide covers what hepatitis C trials exist in 2026, why the field has changed, and resources for any remaining trial needs.
Why hepatitis C trials have decreased
The 2014-2017 introduction of DAAs (sofosbuvir, ledipasvir, glecaprevir-pibrentasvir, sofosbuvir-velpatasvir) achieved unprecedented cure rates. Most major drug development trials concluded successfully, and the field shifted from drug development to:
- Elimination strategies — reaching populations not yet cured
- Treatment in special populations (children, transplant recipients, pregnant women)
- Managing complications in cured patients (HCC surveillance)
- Treatment-resistant cases (rare but exist)
Categories of hepatitis C trials in 2026
Active hepatitis C trials include:
Pediatric hepatitis C: DAA approvals in children continue to expand age ranges.
Pregnancy-related hepatitis C: Treatment during pregnancy and prevention of mother-to-child transmission.
Treatment in special populations: Liver and kidney transplant recipients, HIV co-infected patients, dialysis patients.
Test-and-treat strategies: Population-level interventions for HCV elimination.
Post-cure HCC surveillance: Optimizing surveillance for hepatocellular carcinoma in patients with cirrhosis who’ve cleared HCV.
Reinfection prevention: Strategies for high-risk populations who’ve cleared HCV.
Where to find hepatitis C trials
Resources:
- ClinicalTrials.gov
- American Association for the Study of Liver Diseases
- Hepatitis C Trust
- Major academic hepatology programs
Why most patients don’t need trials anymore
Standard DAA treatment achieves >95% cure rates with 8-12 weeks of oral therapy. Most patients have access to these therapies through insurance or patient assistance programs. The unmet need that drove HCV trials in 2010-2018 has largely been addressed.
If you have hepatitis C, your first option should be standard DAA treatment through your gastroenterologist or hepatologist. Trials are most relevant for:
- Special populations not adequately studied
- Treatment failures (rare but exist)
- Specific research questions about elimination or post-cure management
Frequently Asked Questions
Should I be in an HCV trial or take standard treatment?
Standard DAA treatment is curative for almost all patients. Trials are appropriate for special populations or specific scenarios where standard treatment doesn’t apply.
Are HCV vaccine trials available?
HCV vaccine development continues but has been challenging. Some trials are active but no vaccine is currently close to approval.
What if my treatment failed?
Re-treatment options exist with different DAA regimens. Specialized hepatology consultation is recommended.
Can I be cured of HCV?
Yes. Sustained virologic response (SVR) — undetectable virus 12 weeks after treatment ends — represents cure with current DAAs.
Where do I get HCV treatment?
Through gastroenterologists, hepatologists, infectious disease specialists, and increasingly through primary care. Most insurance covers DAAs.
The bottom line on hepatitis C trials
HCV is one of medicine’s most successful drug development stories. Most patients should pursue standard DAA treatment, which is curative. Trials are limited but exist for special populations and specific research questions.